Hypertonic NSAID Composition for Local Bactericidal and Virucidal Action
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing NSAIDs, such as ibuprofen, have limited bactericidal and virucidal effects against pathogens like P. aeruginosa and S. aureus, and their systemic administration can cause adverse effects, especially in patients with cystic fibrosis, due to interactions with plasma proteins and lipid membranes.
Innovation Solution
A pharmaceutical composition comprising NSAIDs, such as ibuprofen, solubilized in a hypertonic saline solution with a pH between 6.0 and 8.5, administered via nebulization, mouthwash, or topical application, to enhance bactericidal and virucidal effects against Gram+ and Gram- bacteria and lipid-enveloped viruses, reducing interactions with plasma proteins and lipid membranes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NSAIDs are administered systemically to treat inflammatory conditions, then anti-inflammatory and analgesic effects are achieved, but gastrointestinal adverse effects and interactions with plasma proteins occur
Solution Approach 1:
The patent applies local quality by formulating NSAIDs in a specific carrier system (polyol vehicle) with controlled pH and osmolality, enabling localized delivery to the site of infection or inflammation through nebulization or topical application, thereby achieving therapeutic effects while minimizing systemic absorption and associated gastrointestinal adverse effects
Solution Approach 2:
The patent uses an intermediary carrier system consisting of a polyol vehicle with specific additives that mediates the delivery of NSAIDs to the target site. This carrier system controls the release and distribution of the drug, preventing direct contact with the gastrointestinal tract while maintaining therapeutic efficacy through localized action
2Reliability
If NSAIDs are used at high doses to enhance bactericidal activity, then antimicrobial effects improve, but toxicity and adverse effects increase
Solution Approach 1:
The patent applies parameter changes by modifying the physical and chemical parameters of the NSAID formulation, including pH adjustment to specific ranges, selection of appropriate polyol carriers, and control of osmolality. These parameter modifications enhance the bactericidal activity of NSAIDs at lower concentrations by optimizing their interaction with bacterial cell membranes, thereby reducing toxicity while maintaining or improving antimicrobial efficacy
Solution Approach 2:
The patent creates a composite formulation by combining NSAIDs with specific polyol carriers and additives in a controlled ratio. This composite material system enhances the bactericidal activity of the NSAID through synergistic interactions while improving solubility and reducing direct toxicity, achieving effective antimicrobial action at lower drug concentrations
3Quantity of substance
If NSAIDs are solubilized in water to improve bioavailability, then absorption increases, but formation of micelles and amphipathic structures occurs
Solution Approach 1:
The patent uses a polyol carrier as an intermediary substance that facilitates the solubilization of NSAIDs in aqueous solutions without promoting micelle formation. The carrier system acts as a bridge between the hydrophobic NSAID and water, maintaining molecular dispersion and improving bioavailability while preserving compositional stability by preventing self-assembly into micellar structures
4Reliability
If conventional antibiotics are used to treat cystic fibrosis infections, then bacterial clearance is achieved, but development of resistance and systemic side effects occur
Solution Approach 1:
The patent employs a disposable nebulizer or delivery system that provides localized, short-duration treatment directly at the site of infection. This approach eliminates the need for prolonged systemic antibiotic therapy, achieving effective bacterial clearance through localized action while avoiding the development of resistance that occurs with continuous systemic use of conventional antibiotics
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves significant bactericidal and virucidal effects against pathogens associated with cystic fibrosis and Herpes simplex infections with reduced side effects, providing a more effective treatment option without systemic antibiotic use.
Implementation Method 1
solubilized in a hypertonic saline solution
Implementation Method 2
interactions with plasma proteins and lipid membranes
Implementation Method 3
ibuprofen becomes an amphipathic molecule with surfactant properties
Implementation Method 4
surfactant properties with two forms or structures
Implementation Method 5
administered via nebulization
Data Source
AI summary
A bactericidal and virucidal pharmaceutical composition for use on epithelial tissues such as pulmonary, nasal and oral tissues, which comprises a non-steroidal anti-inflammatory drug (NSAID) in a concentration between 5 and 500 mM and a salt, being the NSAID preferably solubilized in a hypertonic saline solution applicable in therapies for viral infections of the Herpes simplex type. The composition can be used in therapies for herpes simplex viral infections, be used as a bactericidal mouthwash, or be vehiculated to the lung by using a nebuliser, for cystic fibrosis.